National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Aurora A kinase inhibitor MLN8237
A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:MLN8237



Previous:Atromid-S, atvogen, Augmentin, Aurimmune, Aurolate
Next:Aurora A kinase/tyrosine kinase inhibitor ENMD-2076, Aurora kinase inhibitor BI 811283, Aurora kinase inhibitor MLN8054, Aurora kinase inhibitor SNS-314, Aurora kinase/VEGFR2 inhibitor CYC116

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov